Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
350 participants
INTERVENTIONAL
2012-10-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will test a new medical device (software) for optimizing treatment of heart failure patients and evaluate its impact on outcome of these patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
telemonitoring
patients in the telemonitoring arm will record vital parameters (blood pressure, heart rate, body weight) and transmit these parameters together with wellbeing and daily dose of heart failure medication
telemonitoring
control
patients in the control arm will not record any vital parameter
control
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
telemonitoring
control
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* treatment with an ACE-inhibitor/angiotensin receptor blocker, beta-blocker, mineralocorticoid receptor antagonist according to current ESC-guidelines
* treatment with a loop diuretic
* stable renal function (eGFR according to MDRD of at least 30ml)
* written informed consent
* minimum age of 18 years
Exclusion Criteria
* planned revascularisation or operation for valvular heart disease within the next 6 months
* planned heart transplantation
* uncontrolled hypertension
* active myocarditis
* malignant disease with a life expectancy of less than 18 months
* chronic use of high-dose NSAID or COX-2-inhibitors
* psychiatric disorders that make it unlikely to understand the protocol
* participation in an other randomized trial
* inability to operate a smartphone
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ludwig Boltzmann Institute for translational heart failure research
UNKNOWN
AIT Austrian Institute of Technology GmbH
OTHER
Medical University of Graz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Friedrich M Fruhwald, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University of Graz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University
Graz, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24-537 ex 11/12
Identifier Type: -
Identifier Source: org_study_id